Regeneron Q2 revenue rises 17% to $4.3 billion; GAAP profit falls 7%
Regeneron reported second quarter 2026 total revenues of $4.3 billion, up 17% from a year earlier, with non-GAAP diluted EPS up 11% to $14.29. GAAP net income fell 7% to $1.3 billion and GAAP diluted EPS fell 5% to $12.23, which the company said included a $1.02 per share negative impact from acquired in-process R&D. The company also narrowed or changed several 2026 guidance items, and it fully repaid the Sanofi Development Balance by the end of the quarter.
Key points
- Total revenues $4.3 billion, up 17%; Dupixent global net sales recorded by Sanofi rose 38% to $6.0 billion
- GAAP net income $1.3 billion, down 7%; non-GAAP net income $1.5 billion, up 8%
- 2026 guidance updated: GAAP gross margin on net product sales now 78%–79% (prior 77%–78%); capital expenditures now $1.030–$1.100 billion (prior $1.100–$1.200 billion)
- Company repurchased $1.2 billion of common stock in the quarter and had $2.5 billion remaining under its repurchase programs as of June 30, 2026
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.